Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

BACKGROUND: The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) model for pediatric rivaroxaban dosing has been constructed...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Thromb J
Päätekijät: Willmann, Stefan, Thelen, Kirstin, Kubitza, Dagmar, Lensing, Anthonie W. A., Frede, Matthias, Coboeken, Katrin, Stampfuss, Jan, Burghaus, Rolf, Mück, Wolfgang, Lippert, Jörg
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6278136/
https://ncbi.nlm.nih.gov/pubmed/30534008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12959-018-0185-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia